心血管疾病风险评估中的非传统危险因素:USPSTF更新证据报告与系统综述
无足够把握度的临床试验评价这些因素对患者健康结局的影响;ABI、hsCRP和CAC可改善判别与重分类,但改善幅度和一致性因因素而异,且临床意义不确定。
要点
- 无足够把握度的临床试验评价非传统危险因素风险评估对健康结局的影响。
- ABI对女性判别改善最大(C统计量变化0.112,NRI 0.096)。
- CAC评分判别与重分类改善最大,但可能将无事件者不恰当重分类为高风险。
核心结论
- 缺乏足够把握度的临床试验评价ABI、hsCRP或CAC评分对风险评估及启动预防治疗的增量效果。
- 风险预测研究中校准、判别和重分类指标的改善其临床意义尚不确定。
研究设计与样本
- 检索MEDLINE、PubMed和Cochrane对照试验中心注册库至2017年5月22日,监测至2018年2月7日。
- 由2名评审员独立进行批判性评价和数据提取。
主要发现
- 无足够把握度的试验评价非传统危险因素风险评估对患者健康结局的临床效果。
- ABI(10项研究)、hsCRP(25项研究)或CAC评分(19项研究)的加入可改善判别和重分类,但改善幅度和一致性因因素而异。
- ABI对女性判别改善最大(C统计量变化0.112,NRI 0.096)。
- hsCRP结果不一致,最大分析(n=166 596)显示对风险预测影响极小(C统计量变化0.0039,NRI 0.0152)。
- CAC评分判别改善最大(C统计量变化范围0.018至0.144),重分类改善最大(NRI范围0.084至0.35),但可能将无心血管事件者不恰当重分类为高风险。
关键数值与推荐
- ABI对女性:C统计量变化0.112,NRI 0.096。
- hsCRP最大分析(n=166 596):C统计量变化0.0039,NRI 0.0152。
- CAC评分:C统计量变化范围0.018至0.144,NRI范围0.084至0.35。
临床怎么用
- 现有证据不足以支持常规使用ABI、hsCRP或CAC评分进行风险评估以指导预防治疗启动。
- 使用CAC评分时需注意可能将无事件者不恰当重分类为高风险。
局限性
- 无足够把握度的临床试验评价非传统危险因素对健康结局的影响。
- 风险预测指标改善的临床意义不确定。
- 危害证据仅限于CAC评分的CT成像(8项研究),显示辐射暴露低但可能导致额外检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Incorporating nontraditional risk factors may improve the performance of traditional multivariable risk assessment for cardiovascular disease (CVD). OBJECTIVE: To systematically review evidence for the US Preventive Services Task Force on the benefits and harms of 3 nontraditional risk factors in cardiovascular risk assessment: the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, and coronary artery calcium (CAC) score. DATA SOURCES: MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials for studies published through May 22, 2017. Surveillance continued through February 7, 2018. STUDY SELECTION: Studies of asymptomatic adults with no known cardiovascular disease. DATA EXTRACTION AND SYNTHESIS: Independent critical appraisal and data abstraction by 2 reviewers. MAIN OUTCOMES AND MEASURES: Cardiovascular events, mortality, risk assessment performance measures (calibration, discrimination, or risk reclassification), and serious adverse events. RESULTS: Forty-three studies (N = 267 244) were included. No adequately powered trials have evaluated the clinical effect of risk assessment with nontraditional risk factors on patient health outcomes. The addition of the ABI (10 studies), hsCRP level (25 studies), or CAC score (19 studies) can improve both discrimination and reclassification; the magnitude and consistency of improvement varies by nontraditional risk factor. For the ABI, improvements in performance were the greatest for women, in whom traditional risk assessment has poor discrimination (C statistic change of 0.112 and net reclassification index [NRI] of 0.096). Results were inconsistent for hsCRP level, with the largest analysis (n = 166 596) showing a minimal effect on risk prediction (C statistic change of 0.0039, NRI of 0.0152). The largest improvements in discrimination (C statistic change ranging from 0.018 to 0.144) and reclassification (NRI ranging from 0.084 to 0.35) were seen for CAC score, although CAC score may inappropriately reclassify individuals not having cardiovascular events into higher-risk categories, as determined by negative nonevent NRI. Evidence for the harms of nontraditional risk factor assessment was limited to computed tomography imaging for CAC scoring (8 studies) and showed that radiation exposure is low but may result in additional testing. CONCLUSIONS AND RELEVANCE: There are insufficient adequately powered clinical trials evaluating the incremental effect of the ABI, hsCRP level, or CAC score in risk assessment and initiation of preventive therapy. Furthermore, the clinical meaning of improvements in measures of calibration, discrimination, and reclassification risk prediction studies is uncertain.
引用
- Lin JS, Evans CV, Johnson E, et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 29998301. doi:10.1001/jama.2018.4242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。